Inozyme Pharma Inc expected to post a loss of 45 cents a share - Earnings Preview

Inozyme Pharma

10/03/2023 11:16

* Inozyme Pharma Inc  INZY.OQ   INZY.O  is expected to show
no
change in quarterly revenue when it reports  results on March 13
(estimated). 
    * 
    * ​Refinitiv's mean analyst estimate for Inozyme Pharma Inc
is for
a loss of 45 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Inozyme
Pharma
Inc is $17.5​, above​ its last closing price of $2.93. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2022  -0.43       -0.43      -0.38     Beat    12.5
 Jun. 30 2022  -0.48       -0.48      -0.38     Beat    20.6
 Mar. 31 2022  -0.82       -0.82      -0.71     Beat    13.6​
 Dec. 31 2021  -0.72       -0.68      -0.79     Missed  -15.3
 ​​Sep.        -0.60       -0.61      -0.60     Beat    1.7
 30 2021                                                
 Jun. 30 2021  -0.57       -0.57      -0.53     Beat    7​
 Mar. 31 2021  -0.54       -0.54      -0.47     Beat    13.2
 Dec. 31 2020              -0.55      -1.01     Missed  -85
 This summary was machine generated March 10 at 11:16 GMT.  All
figures in US dollars  unless otherwise stated